STOCK TITAN
  1. Home
  2. Sec-filings
  3. LYRA
  4. [8-K] Lyra Therapeutics, Inc. Reports Material Event

Lyra Therapeutics (LYRA) hit with sublease default as it winds down

Filing Impact
(High)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Lyra Therapeutics, Inc. reported that on February 23, 2026 it received a notice of default from RVAC Medicines (US), Inc. under its sublease for office space in Waltham, Massachusetts. The default stems from unpaid rent invoices from the master landlord totaling $484,431.92 as of the notice date.

The company previously disclosed that it is ceasing operations and preparing for a wind-down while pursuing strategic options, and has been trying to settle obligations, including lease liabilities, outside a bankruptcy process. Lyra had proposed terminating the sublease with a premises surrender date of January 31, 2026, but no agreement was reached before rent payments stopped.

Lyra states it is continuing to evaluate options regarding the sublease and other outstanding obligations as part of its wind-down. It cautions that there can be no assurance it will successfully negotiate a termination or otherwise resolve these obligations outside of a bankruptcy process, highlighting significant uncertainty around remaining liabilities.

Positive

  • None.

Negative

  • Default and bankruptcy risk: Lyra has received a sublease default notice tied to $484,431.92 of unpaid rent while ceasing operations and warns it may not be able to resolve these obligations outside a bankruptcy process, highlighting severe financial distress and material uncertainty for stakeholders.

Insights

Default notice and wind-down signal elevated bankruptcy risk.

Lyra Therapeutics has received a formal default notice on its Waltham sublease, tied to unpaid rent invoices totaling $484,431.92. This follows the company’s earlier decision to cease operations and pursue strategic options while preparing for a wind-down.

The disclosure confirms Lyra has already stopped rent payments and was unable to finalize a negotiated sublease termination, despite proposing a January 31, 2026 premises surrender date. This suggests constrained liquidity and limited flexibility in meeting remaining lease commitments and other obligations.

The company explicitly warns there is no assurance it can resolve sublease obligations outside of a bankruptcy process. That language, combined with ongoing wind-down activities, underscores heightened restructuring and potential bankruptcy risk until future filings clarify how these liabilities are ultimately addressed.

Item 2.04 Triggering Events That Accelerate or Increase a Direct Financial Obligation Financial
An event triggered acceleration or increase of an existing financial obligation, such as a debt covenant breach.
Understanding 8-K Material Events →
NASDAQ false 0001327273 0001327273 2026-02-23 2026-02-23
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 23, 2026

 

 

Lyra Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

 

Delaware   001-39273   84-1700838
(State or Other Jurisdiction
of Incorporation)		  

(Commission

File Number)

   (IRS Employer
Identification No.)
480 Arsenal Way  
Watertown, Massachusetts   02472
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s Telephone Number, Including Area Code: 617 393-4600

 

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange
on which registered

Common Stock, $0.001 par value per share   LYRA   The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 
 

Item 2.04.

Triggering Events That Accelerate or Increase a Direct Financial Obligation under an Off-Balance Sheet Arrangement.

On February 23, 2026, Lyra Therapeutics, Inc. (the “Company”) received a notice of default from RVAC Medicines (US), Inc. (“RVAC”) under the sublease agreement dated December 21, 2023 (the “Sublease”) between RVAC, as sublessor, and the Company, as sublessee, for office space located at 880 Winter Street, Suite 1002, Waltham, MA 02451 (the “Premises”).

Pursuant to the notice of default, RVAC notified the Company that it has failed to pay the monthly rent due under the Sublease. RVAC received two invoices from Boston Properties Limited Partnership (“BXP”), the master landlord, dated February 1, 2026 and March 1, 2026, each in the amount of $242,215.96, indicating rent due for the Premises. The aggregate unpaid rent under the Sublease totals $484,431.92 as of the date of the notice.

As previously disclosed, on January 12, 2026, the Company announced that it is ceasing operations and, in connection with its pursuit of strategic options, has begun preparations for a wind-down of the Company. In connection with the wind-down, the Company has been seeking to resolve its outstanding obligations, including its lease obligations, ideally outside of a bankruptcy process. The Company had previously submitted a proposal to RVAC to terminate the Sublease, which included a premises surrender date of January 31, 2026, among other terms. However, the parties were unable to reach an agreement prior to the Company ceasing rent payments.

The Company is continuing to evaluate its options with respect to the Sublease and its other outstanding obligations as part of its wind-down activities. There can be no assurance that the Company will be able to successfully negotiate a termination of the Sublease or otherwise resolve its obligations thereunder outside of a bankruptcy process.

Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Current Report on Form 8-K that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the Company’s ability to successfully negotiation a termination of the Sublease or otherwise resolve its obligations outside of the bankruptcy process. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential,” “would” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words or expressions. For other important factors that could cause actual results to differ materially from the forward-looking statements in this Current Report on Form 8-K, please see the risks and uncertainties identified under the heading “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024, as updated by the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, each of which is available on the Company’s Investor Relations website at investors.lyratherapeutics.com and on the SEC website at www.sec.gov. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. All forward-looking statements reflect the Company’s beliefs and assumptions only as of the date of this Current Report on Form 8-K. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances, or otherwise. Capitalized terms shall have the meanings ascribed to such terms in this Current Report on Form 8-K.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

      Lyra Therapeutics, Inc.
Date: February 27, 2026     By:  

/s/ Jason Cavalier

      Jason Cavalier, Authorized Signatory

Source: View Original Filing on SEC EDGAR

FAQ

What did Lyra Therapeutics (LYRA) disclose in this 8-K filing?

Lyra Therapeutics disclosed it received a notice of default from RVAC Medicines under its Waltham office sublease due to unpaid rent totaling $484,431.92. The company is winding down operations and evaluating how to address this and other obligations, with no assurance of avoiding a bankruptcy process.

How much unpaid rent does Lyra Therapeutics (LYRA) owe under the RVAC sublease?

Lyra reported aggregate unpaid rent of $484,431.92 under the RVAC sublease. This amount reflects two invoices from the master landlord, dated February 1, 2026 and March 1, 2026, each for $242,215.96, covering rent for the Waltham, Massachusetts premises.

Is Lyra Therapeutics (LYRA) ceasing operations according to the filing?

Yes, Lyra previously announced it is ceasing operations and preparing for a wind-down while pursuing strategic options. As part of that process, it is seeking to resolve outstanding obligations, including lease liabilities, and is now facing a sublease default related to unpaid rent at its Waltham office space.

What was Lyra Therapeutics’ (LYRA) proposal regarding the RVAC sublease?

Lyra previously submitted a proposal to RVAC to terminate the sublease, which included a premises surrender date of January 31, 2026 and other terms. The parties did not reach an agreement before Lyra ceased paying rent, leading to the default notice described in the filing.

Where is the leased property involved in Lyra Therapeutics’ (LYRA) default located?

The subleased premises are located at 880 Winter Street, Suite 1002, Waltham, Massachusetts 02451. Lyra is the sublessee under a sublease with RVAC Medicines, while Boston Properties Limited Partnership is the master landlord issuing the rent invoices referenced in the default notice.

Filing Exhibits & Attachments

3 documents

Other Documents